Sumitomo Pharma Oncology presented new data from the ongoing Phase 1/2 study evaluating TP-3654.

Sumitomo Pharma Oncology to Present Preliminary Clinical Data Evaluating Investigational Agent TP-3654

Sumitomo Pharma Oncology recently announced the U.S. FDA granted Orphan Drug Designation for DSP-0390, an investigational emopamil-binding protein (EBP) inhibitor for the treatment of brain cancer.